Home › Companies › Halozyme Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Halozyme Therapeutics, Inc.’s Form 8-K, filed May 7, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of May 5, 2026: 4 items on Halozyme Therapeutics, Inc.’s Form 8-K, filed May 7, 2026: 2 approved · 2 passed (calculated).
Notable dissent: 1 director (11.0% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Explore Halozyme Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Halozyme Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 7, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Bernadette Connaughton | 89,053,734 | 5,068,160 | 127,131 | -- | 9,889,219 | 95% | Passed (calculated) | — |
| Elect Director: Matthew L. Posard | 82,739,433 | 10,236,878 | 1,272,714 | -- | 9,889,219 | 89% | Passed (calculated) | — |
| 2. Advisory vote on the compensation of the Company's named executive officers | 84,682,518 | 9,311,426 | 255,081 | -- | 9,889,219 | 90% | Approved | — |
| 3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 103,197,579 | 849,433 | 91,232 | -- | -- | 99.2% | Approved | — |
Source: Halozyme Therapeutics, Inc., Form 8-K, filed with the SEC on May 7, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
601 asset managers disclosed a vote on at least one Halozyme Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
95% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Bernadette Connaughton
Halozyme Therapeutics, Inc.’s own tally for this item (“Elect Director: Bernadette Connaughton”): 89,053,734 for, 5,068,160 against, per its Form 8-K filed May 7, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 145 asset managers below reported 45,116,992 for, 1,629,505 against, 31,020 abstained, 90 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,406,613 | 11 | 0 | 0 | For |
| BlackRock | 7,468,246 | 0 | 0 | 0 | For |
| Fidelity | 2,427,364 | 0 | 0 | 0 | For |
| Invesco | 2,371,379 | 0 | 0 | 0 | For |
| State Street | 2,337,907 | 0 | 0 | 0 | For |
| First Trust | 1,487,656 | 0 | 0 | 0 | For |
| John Hancock | 137,158 | 1,168,773 | 0 | 0 | Mixed |
| Charles Schwab | 1,257,706 | 0 | 0 | 0 | For |
| Federated Hermes | 1,113,851 | 0 | 0 | 0 | For |
| Capitol Series Trust | 898,255 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 875,241 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 849,734 | 0 | 0 | 0 | For |
| Capital Group | 830,385 | 0 | 0 | 0 | For |
| Putnam | 561,194 | 0 | 0 | 0 | For |
| TIAA | 551,184 | 0 | 0 | 0 | For |
| Dimensional | 521,318 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 433,965 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 313,876 | 101,043 | 0 | 0 | Mixed |
| Jackson National | 407,549 | 0 | 0 | 0 | For |
| Nationwide | 380,986 | 0 | 0 | 0 | For |
| EA Series Trust | 379,284 | 0 | 0 | 0 | For |
| Calamos | 349,930 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 347,050 | 0 | 0 | 0 | For |
| Victory Capital | 325,289 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 321,070 | 0 | 0 | 0 | For |
Showing the 25 largest of 145 asset managers. All 145 are in the interactive database (link above).
Combines 5 wordings of this item as funds reported it.
89% Majority: yes · of votes cast
Description as filed by funds: Election of Class I Directors: Matthew L. Posard
Halozyme Therapeutics, Inc.’s own tally for this item (“Elect Director: Matthew L. Posard”): 82,739,433 for, 10,236,878 against, per its Form 8-K filed May 7, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a majority of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 145 asset managers below reported 42,565,188 for, 4,181,306 against, 31,023 abstained, 90 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,400,139 | 6,482 | 3 | 0 | For |
| BlackRock | 7,468,246 | 0 | 0 | 0 | For |
| Fidelity | 2,427,364 | 0 | 0 | 0 | For |
| Invesco | 2,371,379 | 0 | 0 | 0 | For |
| State Street | 20,564 | 2,317,343 | 0 | 0 | Against |
| First Trust | 1,487,656 | 0 | 0 | 0 | For |
| John Hancock | 137,158 | 1,168,773 | 0 | 0 | Mixed |
| Charles Schwab | 1,257,706 | 0 | 0 | 0 | For |
| Federated Hermes | 1,113,851 | 0 | 0 | 0 | For |
| Capitol Series Trust | 898,255 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 875,241 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 849,734 | 0 | 0 | 0 | For |
| Capital Group | 830,385 | 0 | 0 | 0 | For |
| Putnam | 561,194 | 0 | 0 | 0 | For |
| TIAA | 551,184 | 0 | 0 | 0 | For |
| Dimensional | 521,318 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 433,965 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 313,876 | 101,043 | 0 | 0 | Mixed |
| Jackson National | 407,549 | 0 | 0 | 0 | For |
| Nationwide | 380,986 | 0 | 0 | 0 | For |
| EA Series Trust | 379,284 | 0 | 0 | 0 | For |
| Calamos | 349,930 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 347,050 | 0 | 0 | 0 | For |
| Victory Capital | 325,289 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 321,070 | 0 | 0 | 0 | For |
Showing the 25 largest of 145 asset managers. All 145 are in the interactive database (link above).
Combines 15 wordings of this item as funds reported it.
90% Approved · of votes cast
Prior year: 96.1% for (May 1, 2025 meeting) ▼ 6.0 pts
Description as filed by funds: To approve, by a non-binding advisory vote, the compensation of the Company's named executive officers.
Halozyme Therapeutics, Inc.’s own tally for this item (“2. The advisory vote on the compensation of the Company's named executive officers”): 84,682,518 for, 9,311,426 against — passed, per its Form 8-K filed May 7, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 90% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,406,613 | 10 | 0 | 0 | For |
| BlackRock | 7,468,246 | 0 | 0 | 0 | For |
| Fidelity | 2,427,364 | 0 | 0 | 0 | For |
| Invesco | 2,371,379 | 0 | 0 | 0 | For |
| State Street | 20,673 | 2,317,234 | 0 | 0 | Against |
| First Trust | 1,487,656 | 0 | 0 | 0 | For |
| John Hancock | 1,305,931 | 0 | 0 | 0 | For |
| Charles Schwab | 1,257,706 | 0 | 0 | 0 | For |
| Federated Hermes | 1,113,851 | 0 | 0 | 0 | For |
| Capitol Series Trust | 898,255 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 875,241 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 849,734 | 0 | 0 | 0 | For |
| Capital Group | 830,385 | 0 | 0 | 0 | For |
| Putnam | 561,194 | 0 | 0 | 0 | For |
| TIAA | 551,184 | 0 | 0 | 0 | For |
| Dimensional | 521,318 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 433,965 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 414,919 | 0 | 0 | 0 | For |
| Jackson National | 407,549 | 0 | 0 | 0 | For |
| Nationwide | 380,986 | 0 | 0 | 0 | For |
| EA Series Trust | 379,284 | 0 | 0 | 0 | For |
| Calamos | 349,930 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 347,050 | 0 | 0 | 0 | For |
| Victory Capital | 325,289 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 321,070 | 0 | 0 | 0 | For |
Fund voting reports, all 145 managers: 44,065,605 for, 2,614,702 against, 31,020 abstained, 120 not voted. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| State Street | 61,481 | 4,760,960 | 0 | 0 | Against |
| BlackRock | 3,386,988 | 1,579 | 0 | 0 | For |
| Invesco | 3,056,452 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,468,793 | 0 | 0 | 0 | For |
| SNYDER CAPITAL MANAGEMENT L P | 2,153,875 | 0 | 0 | 0 | For |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2,098,221 | 0 | 0 | 0 | For |
| Boston Partners | 2,028,881 | 0 | 0 | 0 | For |
| Janus Henderson | 1,845,794 | 0 | 0 | 0 | For |
| AllianceBernstein | 1,691,604 | 0 | 0 | 0 | For |
| JUPITER ASSET MANAGEMENT LTD | 1,567,242 | 0 | 0 | 0 | For |
| Federated Hermes | 1,534,163 | 0 | 0 | 0 | For |
| FULLER & THALER ASSET MANAGEMENT, INC. | 1,344,686 | 0 | 0 | 0 | For |
| Charles Schwab | 1,276,616 | 0 | 0 | 0 | For |
| GW&K Investment Management, LLC | 228,358 | 0 | 0 | 0 | For |
| CONGRESS ASSET MANAGEMENT CO | 1,200,563 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 1,125,605 | 0 | 0 | 0 | For |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1,095,740 | 0 | 0 | 0 | For |
| Stephens Investment Management Group LLC | 1,005,872 | 0 | 0 | 0 | For |
| Vanguard | 949,698 | 0 | 0 | 0 | For |
| Northern Trust | 924,622 | 0 | 0 | 0 | For |
| Putnam | 846,808 | 0 | 0 | 0 | For |
| Capital Group | 830,385 | 0 | 0 | 0 | For |
| LOS ANGELES CAPITAL MANAGEMENT LLC | 753,716 | 0 | 0 | 0 | For |
| UBS | 0 | 644,161 | 0 | 0 | Against |
| Handelsbanken Fonder AB | 591,869 | 0 | 0 | 0 | For |
Institutional-manager reports, all 486 managers: 51,280,504 for, 6,885,808 against, 94,279 abstained, 23,173 not voted, 1,030,053 mixed. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.2% Approved · of votes cast
Prior year: 99.4% for (May 1, 2025 meeting) ▼ 0.2 pts
Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Halozyme Therapeutics, Inc.’s own tally for this item (“3. A proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 103,197,579 for, 849,433 against — passed, per its Form 8-K filed May 7, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The foregoing proposal was approved.”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Also reported under other wordings, matched to the same row of Halozyme Therapeutics, Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).
The 145 asset managers below reported 46,739,895 for, 6,602 against, 31,020 abstained, 90 not voted.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 11,400,153 | 6,471 | 0 | 0 | For |
| BlackRock | 7,468,246 | 0 | 0 | 0 | For |
| Fidelity | 2,427,364 | 0 | 0 | 0 | For |
| Invesco | 2,371,379 | 0 | 0 | 0 | For |
| State Street | 2,337,798 | 109 | 0 | 0 | For |
| First Trust | 1,487,656 | 0 | 0 | 0 | For |
| John Hancock | 1,305,931 | 0 | 0 | 0 | For |
| Charles Schwab | 1,257,706 | 0 | 0 | 0 | For |
| Federated Hermes | 1,113,851 | 0 | 0 | 0 | For |
| Capitol Series Trust | 898,255 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 875,241 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 849,734 | 0 | 0 | 0 | For |
| Capital Group | 830,385 | 0 | 0 | 0 | For |
| Putnam | 561,194 | 0 | 0 | 0 | For |
| TIAA | 551,184 | 0 | 0 | 0 | For |
| Dimensional | 521,318 | 0 | 0 | 0 | For |
| WILLIAM BLAIR FUNDS | 433,965 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 414,919 | 0 | 0 | 0 | For |
| Jackson National | 407,549 | 0 | 0 | 0 | For |
| Nationwide | 380,986 | 0 | 0 | 0 | For |
| EA Series Trust | 379,284 | 0 | 0 | 0 | For |
| Calamos | 349,930 | 0 | 0 | 0 | For |
| PROFESSIONALLY MANAGED PORTFOLIOS | 347,050 | 0 | 0 | 0 | For |
| Victory Capital | 325,289 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 321,070 | 0 | 0 | 0 | For |
Showing the 25 largest of 145 asset managers. All 145 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 118,523,000 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.62% |
| 2 | BlackRock | 6.30% |
| 3 | Fidelity | 2.05% |
| 4 | Invesco | 2.00% |
| 5 | State Street | 1.97% |
| 6 | First Trust | 1.26% |
| 7 | John Hancock | 1.10% |
| 8 | Charles Schwab | 1.06% |
| 9 | Federated Hermes | 0.94% |
| 10 | Capitol Series Trust | 0.76% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | State Street | 4.07% |
| 2 | BlackRock | 2.86% |
| 3 | Invesco | 2.58% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 2.08% |
| 5 | SNYDER CAPITAL MANAGEMENT L P | 1.82% |
| 6 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 1.77% |
| 7 | Boston Partners | 1.71% |
| 8 | Janus Henderson | 1.56% |
| 9 | AllianceBernstein | 1.43% |
| 10 | JUPITER ASSET MANAGEMENT LTD | 1.32% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 13,265,053 | 11.19% | Form 13F, quarter ended March 31, 2026 |
| Vanguard Group | 11,566,896 | 9.76% | Form 13F, quarter ended March 31, 2026 |
| State Street Corporation | 6,053,007 | 5.11% | Proxy statement (DEF 14A), table as of March 9, 2026 |
| Invesco | 4,012,494 | 3.39% | Form 13F, quarter ended March 31, 2026 |
| Morgan Stanley | 2,658,299 | 2.24% | Form 13F, quarter ended March 31, 2026 |
| Helen I. Torley | 2,208,873 | 1.86% | Proxy statement (DEF 14A), table as of March 9, 2026 |
| Dimensional Fund Advisors | 2,079,827 | 1.75% | Form 13F, quarter ended March 31, 2026 |
| D.E. Shaw | 1,899,408 | 1.60% | Form 13F, quarter ended March 31, 2026 |
| Two Sigma | 1,584,961 | 1.34% | Form 13F, quarter ended March 31, 2026 |
| Charles Schwab | 1,289,533 | 1.09% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 118,523,000 shares outstanding, as reported by Halozyme Therapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Halozyme Therapeutics, Inc.'s shareholder meeting held May 5, 2026, in the 2025-2026 proxy season, 601 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 2,974 separate fund positions. On the most widely held item on that ballot — To approve, by a non-binding advisory vote, the compensation of the Company's named executive… — Halozyme Therapeutics, Inc.'s filing reports the proposal as approved, with 90% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Halozyme Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 7, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Halozyme Therapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Halozyme Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Halozyme Therapeutics (HALO) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/halozyme-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.